|Printable version||E-mail this to a friend|
Cancer Research UK - Tumour cells in blood samples could predict prostate cancer spread
Researchers have found a group of circulating tumour cells in prostate cancer patient blood samples which are linked to the spread of the disease, according to new research* presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.
This is the first time these cell types have been shown to be a promising marker for prostate cancer spread.
In a study of around 80 samples from men with prostate cancer, scientists at the Barts Cancer Institute at Queen Mary University looked for cells that were gaining the ability to migrate and invade through the body.**
Samples with more of these cells were more likely to come from patients whose cancer had spread or was more aggressive.
This means that, in the future, these particular cells could potentially be used as a marker to monitor prostate cancer patients and predict if the disease is going to spread – alongside other monitoring techniques.
There are around 46,500 new cases of prostate cancer each year in the UK, and around 11,000 people die from the disease each year.
Dr Yong-Jie Lu, lead author from QMUL’s Barts Cancer Institute, said: “Our research shows that the number of these specific cells in a patient’s sample is a good indicator of prostate cancer spreading. By identifying these cells, which have gained the ability to move through the body, we have found a potential new way to monitor the disease.
“If we’re able to replicate these studies in larger groups of people, we may be able to one day predict the risk of someone’s cancer spreading so they can make more informed treatment decisions.”
Dr Chris Parker, Chair of the NCRI's Prostate Cancer Clinical Studies Group, said: “There’s a need to develop better tests to identify and monitor men with aggressive prostate cancer. This research has found a promising new marker that could one day make it to the clinic to guide treatment decisions.”
This research was funded by Orchid Cancer Appeal, ANGLE plc and Chinese Scholarship Council. The scientists used a highly innovative cell separation technology Parsortix™, developed by UK company ANGLE plc that is able to capture the circulating tumour cells.
Notes to Editor
* Abstract: Capture of circulating tumour cells with epithelial and mesenchymal features for prostate cancer prognosis
** This is known as epithelial to mesenchymal transition (EMT).
Latest News from
Cancer Research UK - Lifetime weight gain linked to oesophageal and stomach cancers16/02/2017 15:35:00
People who are overweight in their twenties and become obese later in life may be three times more likely to develop cancer of either the oesophagus (food pipe) or upper stomach, according to a study published in the British Journal of Cancer on Wednesday.
Age UK - 'Borrowed time' to save social care system from collapse16/02/2017 11:35:00
A new report from Age UK has concluded that we are living on borrowed time to save the social care system for older people.
Cancer Research UK - NHS cancer treatment target in England missed for third consecutive year14/02/2017 12:35:00
The ’62 day’ waiting time target for cancer patients in England has been missed again, marking 3 years since the target was last met.
Cancer Research UK - More support needed for GPs to make best use of cancer preventing drugs14/02/2017 10:35:00
A new Cancer Research UK report reveals that GPs want more support when offering drugs that lower the risk of certain cancers.